Abbisko Therapeutics to Present CSF-1R Inhibitor ABSK021 Data at CTOS Annual Meeting
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it will present data...
Cancer
Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting
Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...
I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...
Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation
The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...
Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China
The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial
China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...
BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences
Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...
Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...
CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026
China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...
GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment
Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...
CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...
Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...